




a
ALVEOLI HTE Cluster Overlap: LCA & HC



ALVEOLI HTE Cluster Overlap: LCA & XL RF




ALVEOLI HTE Cluster Overlap: XL RF & HC



■ Harm
■ Benefit


b

FACTT HTE Cluster Overlap: LCA & PAM




Agreement: 39.7 %

FACTT HTE Cluster Overlap: LCA & CF




Agreement: 70.0%

FACTT HTE Cluster Overlap: LCA & XL RF




Agreement: 67.2%

FACTT HTE Cluster Overlap: LCA & XL BART




Agreement: 53.5%

FACTT HTE Cluster Overlap: CF & PAM



Agreement: 40.6%


FACTT HTE Cluster Overlap: XL RF & PAM



Agreement: 45.7%

c

FACTT HTE Cluster Overlap: XL BART & PAM




Agreement: 55.8%

FACTT HTE Cluster Overlap: CF & XL RF




Agreement: 81.9%

FACTT HTE Cluster Overlap: CF & XL BART




Agreement: 65.4%

FACTT HTE Cluster Overlap: XL RF & XL BART




Agreement: 69.3%

FACTT HTE Cluster Overlap: LCA w/ & w/o Bio



Agreement: 84.0%

d
SAILS HTE Cluster Overlap: Kmeans & CF



Agreement: 61.5 %